{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:06:13Z","timestamp":1768485973802,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jpba.2024.116079","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T02:24:37Z","timestamp":1709346277000},"page":"116079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Simultaneous determination of iguratimod and its metabolite in rat plasma using a UPLC-MS\/MS method: Application for drug-drug interaction"],"prefix":"10.1016","volume":"243","author":[{"given":"Lu","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hualu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghua","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren-ai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congrong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.116079_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fphar.2020.00073","article-title":"Iguratimod as a new drug for rheumatoid arthritis: current landscape","volume":"11","author":"Xie","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jpba.2024.116079_bib2","article-title":"The effect and safety of iguratimod combined with methotrexate on rheumatoid arthritis: a systematic review and meta-analysis based on a randomized controlled trial","volume":"12","author":"Zeng","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.jpba.2024.116079_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/03009742.2020.1809701","article-title":"Efficacy and safety of iguratimod on patients with primary Sj\u00f6gren's syndrome: a randomized, placebo-controlled clinical trial","volume":"50","author":"Shao","year":"2021","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.jpba.2024.116079_bib4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1080\/14397595.2020.1789335","article-title":"Iguratimod treatment reduces disease activity in early primary Sj\u00f6gren's syndrome: an open-label pilot study","volume":"31","author":"Chen","year":"2021","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jpba.2024.116079_bib5","first-page":"7544","article-title":"Efficacy and safety of iguratimod combined with methylprednisolone for primary Sjogren's syndrome: a meta-analysis and trial sequential analysis","volume":"27","author":"Hu","year":"2023","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.jpba.2024.116079_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.924730","article-title":"A systematic review and meta-analysis of 19 randomized controlled trials of iguratimod combined with other therapies for Sjogren's syndrome","volume":"13","author":"Zeng","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.jpba.2024.116079_bib7","article-title":"Randomised, double-blind, placebo-controlled study of iguratimod in the treatment of active spondyloarthritis","volume":"8","author":"Li","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.jpba.2024.116079_bib8","first-page":"631","article-title":"Preparation of a major metabolite of iguratimod and simultaneous assay of iguratimod and its metabolite by HPLC in rat plasma","volume":"18","author":"Han","year":"2019","journal-title":"Iran. J. Pharm. Res.: IJPR"},{"key":"10.1016\/j.jpba.2024.116079_bib9","first-page":"1455","article-title":"Effects of iguratimod on warfarin, diclofenac, and celecoxib metabolism, and prediction of in vivo drug-drug interactions, Japanese","volume":"45","author":"Kato","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2024.116079_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011322","article-title":"Advances in the treatment of invasive fungal disease","volume":"19","author":"Zhang","year":"2023","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jpba.2024.116079_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13052-023-01460-5","article-title":"The efficacy and safety of fluconazole in preventing invasive fungal infection in very low birth weight infants: a systematic review and meta-analysis","volume":"49","author":"Xie","year":"2023","journal-title":"Ital. J. Pedia"},{"key":"10.1016\/j.jpba.2024.116079_bib12","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1248\/bpb.28.1805","article-title":"Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes","volume":"28","author":"Niwa","year":"2005","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jpba.2024.116079_bib13","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/bmc.921","article-title":"Determination of iguratimod in rat plasma by high performance liquid chromatography: method and application","volume":"22","author":"Zhou","year":"2008","journal-title":"Biomed. Chromatogr.: BMC"},{"key":"10.1016\/j.jpba.2024.116079_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4277","article-title":"A rapid and sensitive LC-MS\/MS method for analysis of iguratimod in human plasma: application to a pharmacokinetic study in Chinese healthy volunteers","author":"Xia","year":"2018","journal-title":"Biomed. Chromatogr.: BMC"},{"key":"10.1016\/j.jpba.2024.116079_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jpba.2018.12.036","article-title":"UPLC-MS\/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma","volume":"166","author":"Xu","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116079_bib16","doi-asserted-by":"crossref","first-page":"8218","DOI":"10.1016\/j.arabjc.2020.09.056","article-title":"UPLC-MS\/MS for simultaneous quantification of vortioxetine and its metabolite Lu AA34443 in rat plasma and its application to drug interactions","volume":"13","author":"Gu","year":"2020","journal-title":"Arab J. Chem."},{"key":"10.1016\/j.jpba.2024.116079_bib17","article-title":"Effect of baicalein on the pharmacokinetics of cilostazol and its two metabolites in rat plasma using UPLC-MS\/MS method","volume":"13","author":"Weng","year":"2022","journal-title":"Front Pharm."},{"key":"10.1016\/j.jpba.2024.116079_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2019.113003","article-title":"Simultaneous determination of illegal drug substances in dietary supplements for gout and osteoporosis using ultra-performance liquid chromatography and liquid chromatography-quadrupole-time-of-flight mass spectrometry","volume":"179","author":"Kim","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116079_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113613","article-title":"Simultaneous measurement of acalabrutinib, ibrutinib, and their metabolites in beagle dog plasma by UPLC-MS\/MS and its application to a pharmacokinetic study","volume":"191","author":"Jiang","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116079_bib20","unstructured":"Bioanalytical Method Validation, Food and Drug Administration, 2018, available at: \u3008https:\/\/www.fda.gov\/media\/70858\/download\u3009."},{"key":"10.1016\/j.jpba.2024.116079_bib21","unstructured":"European Medicines Agency, Guideline on Bioanalytical Method Validation, Committee for Medicinal Products for Human Use (CHMP), 2011, Available online: \u3008https:\/\/www.ema.europa.eu\/en\/bioanalytical-method-validation\u3009 (Accessed 1 February 2021)."},{"key":"10.1016\/j.jpba.2024.116079_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2023.110531","article-title":"Effects of CYP2C19 inhibitors on mavacamten pharmacokinetics in rats based on UPLC-MS\/MS","volume":"380","author":"Li","year":"2023","journal-title":"Chem. -Biol. Interact."},{"key":"10.1016\/j.jpba.2024.116079_bib23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00280-022-04464-w","article-title":"Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults","volume":"90","author":"Chen","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2024.116079_bib24","article-title":"Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions","volume":"34","author":"Umehara","year":"2019","journal-title":"Drug Metab. Pers. Ther."},{"key":"10.1016\/j.jpba.2024.116079_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s13318-019-00581-9","article-title":"Effect of fluconazole and itraconazole on the pharmacokinetics of erdafitinib in healthy adults: a randomized, open-label, drug-drug interaction study","volume":"45","author":"Poggesi","year":"2020","journal-title":"Eur. J. Drug Metab. Pharmacokinet."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524001195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524001195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T20:05:00Z","timestamp":1715285100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524001195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":25,"alternative-id":["S0731708524001195"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116079","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous determination of iguratimod and its metabolite in rat plasma using a UPLC-MS\/MS method: Application for drug-drug interaction","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116079"}}